Overview

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001
Phase:
Phase 2
Details
Lead Sponsor:
Collaborative Medicinal Development Pty Limited
Treatments:
Copper